CDC73相关疾病:原发性甲状旁腺功能亢进症中的临床表现与病例检出
这项荷兰全国性回顾性队列研究分析了89例接受胚系CDC73分析的原发性甲状旁腺功能亢进症(pHPT)患者及43例后续检测证实为突变携带者的亲属。在89例转诊pHPT患者中检出11例(12.4%)致病性胚系CDC73变异;43例非先证者突变携带者中,CDC73相关疾病至50岁时估计外显率为65%(95%CI 48%~82%)。作者推荐对(疑似)HPT-JT综合征、家族性孤立性pHPT、不典型或恶性甲状旁腺组织学及年轻pHPT患者进行胚系CDC73分析。
要点
- 89例转诊pHPT患者中检出11例(12.4%)致病性胚系CDC73变异。
- 43例非先证者突变携带者至50岁时CDC73相关疾病估计外显率为65%(95%CI 48%~82%)。
- 作者推荐对(疑似)HPT-JT综合征、家族性孤立性pHPT、不典型或恶性甲状旁腺组织学及年轻pHPT患者行胚系CDC73分析。
核心结论
- 作者推荐对(疑似)HPT-JT综合征、家族性孤立性pHPT、不典型或恶性甲状旁腺组织学及年轻pHPT患者进行胚系CDC73分析,以提高突变检出并优化临床管理、遗传咨询及高危家属监测。
研究设计与样本
- 荷兰全国性回顾性队列研究,在三级转诊中心开展。
- 研究纳入89例因pHPT转诊接受胚系CDC73分析的患者,以及43例后续检测证实为突变携带者的亲属。
主要发现
- 89例转诊pHPT患者中检出11例(12.4%)致病性胚系CDC73变异。
- 11例突变携带者中,(疑似)甲状旁腺功能亢进-颌骨肿瘤(HPT-JT)综合征3例,家族性孤立性pHPT 5例,貌似散发性甲状旁腺癌2例,貌似散发性甲状旁腺腺瘤1例。
- 43例非先证者突变携带者中,CDC73相关疾病至50岁时估计外显率为65%(95%置信区间48%~82%)。
临床怎么用
- 作者推荐对(疑似)HPT-JT综合征、家族性孤立性pHPT、不典型或恶性甲状旁腺组织学及年轻pHPT患者进行胚系CDC73分析。
- 作者认为这些标准可提高胚系CDC73突变检出,有助于pHPT的最佳临床管理及对高危家属的遗传咨询和监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Heterozygous pathogenic germline variants in CDC73 predispose to the development of primary hyperparathyroidism (pHPT) and, less frequently, ossifying fibroma of the jaw and renal and uterine tumors. Clinical information on CDC73-related disorders has so far been limited to small case series. OBJECTIVE: To assess the clinical manifestations and penetrance in CDC73-related disorders and to improve case detection in pHPT. DESIGN: Nationwide retrospective Dutch cohort study. SETTING: Tertiary referral center. PATIENTS: We studied 89 patients with pHPT referred for germline CDC73 analysis and 43 subsequently tested relatives who proved to be mutation carriers. INVESTIGATION: Germline CDC73 mutation analysis. MEAN OUTCOME: CDC73 mutation detection yield, referral rate, and CDC73-related disease penetrance. RESULTS: Pathogenic germline CDC73 variants were identified in 11 of the 89 referred pHPT patients (12.4%), with (suspected) hyperparathyroidism-jaw tumor (HPT-JT) syndrome (n = 3), familial isolated pHPT (n = 5), apparently sporadic parathyroid carcinoma (n = 2), and apparently sporadic parathyroid adenoma (n = 1). The estimated penetrance of CDC73-related disorders was 65% at age 50 years (95% confidence interval, 48% to 82%) in 43 nonindex mutation carriers. CONCLUSIONS: Germline CDC73 analysis is recommended in individuals with (suspected) HPT-JT syndrome, familial isolated pHPT, atypical or malignant parathyroid histology, and young individuals with pHPT. These criteria would increase germline CDC73 mutation detection, enabling optimal clinical management of pHPT as well as genetic counseling and surveillance for family members at risk for developing CDC73-related disorders.
引用
- van der Tuin K, Tops CMJ, Adank MA, et al. CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2017. PMID: 29040582. doi:10.1210/jc.2017-01249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。